Related Experiment Video
Updated: May 6, 2026
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Preclinical models for drug selection in myeloproliferative neoplasms
Niccolò Bartalucci1, Costanza Bogani, Alessandro M Vannucchi
1Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Abstract:
The discovery that an abnormally activated JAK-STAT signaling pathway is central to the pathogenesis of myeloproliferative neoplasms has promoted the clinical development of small-molecule JAK2 inhibitors. These agents have shown remarkable efficacy in disease control, but do not induce molecular remission; on the other hand, interferon holds the promise to target the putative hematopoietic progenitor cell initiating the disease. The presence of additional molecular abnormalities indicates a high molecular complexity of myeloproliferative neoplasms, and the need for simultaneously targeting different targets. Several drugs are currently under study as single agents and in combination. This review briefly describes the several in vitro and in vivo models of myeloproliferative neoplasms that are being used as preclinical models for drug development.
Insights
Small-molecule JAK2 inhibitors show promise for myeloproliferative neoplasms but don't achieve molecular remission. Interferon may target disease-initiating cells, suggesting combination therapies are needed.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway is critically involved in the development of myeloproliferative neoplasms (MPNs).
- Abnormal JAK-STAT activation drives MPN pathogenesis, leading to the development of targeted therapies.
Purpose of the Study:
- To review preclinical models for developing novel therapies for myeloproliferative neoplasms.
- To discuss the limitations of current JAK2 inhibitors and the potential of alternative therapeutic strategies.
Main Methods:
- Review of in vitro and in vivo preclinical models used for drug development in MPNs.
- Analysis of the efficacy and limitations of JAK2 inhibitors and interferon in MPN treatment.
Main Results:
- Small-molecule JAK2 inhibitors effectively control MPN but do not induce molecular remission.
- Interferon shows potential in targeting the disease-initiating hematopoietic progenitor cells.
- MPNs exhibit molecular complexity with multiple abnormalities, necessitating combination therapies.
Conclusions:
- Targeting the JAK-STAT pathway with JAK2 inhibitors is a validated strategy for MPN management.
- Combination therapies, potentially including interferon, are crucial for achieving molecular remission in MPNs.
- Preclinical models are essential for advancing the development of effective treatments for MPNs.
